Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial - The Lancet Oncology
Cancers | Free Full-Text | Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
Targeting BRAF Mutation Positive Cancers: Melanoma, Lung and Colorectal | Roswell Park Comprehensive Cancer Center - Buffalo, NY
![PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c096f23cc88dea1f4635eb820fb4548ab1056b0f/4-Figure1-1.png "PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar")
PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar
The MAPK pathway and the role of BRAF and MEK inhibitors. | Download Scientific Diagram
MEK inhibitors for the treatment of non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Clinical Development of BRAF plus MEK Inhibitor Combinations: Trends in Cancer
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma - Lim - 2017 - Cancer - Wiley Online Library
Mechanisms of acquired resistance to BRAF-MEK inhibitors. Multiple... | Download Scientific Diagram
Combined BRAF and MEK Inhibition for Patients with Advanced Melanoma
A combined therapy improves survival in patients with metastatic melanoma | Hospital Clínic Barcelona
Frontiers | BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review | JACC: CardioOncology
Systemic treatment for BRAF-mutant melanoma: where do we go next? - The Lancet Oncology
Cancers | Free Full-Text | Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials - The ASCO Post
Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4 | IntechOpen
Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms | Bentham Science
BRAF Alterations in Primary Brain Tumors - Stefania Maraka - Discovery Medicine
BRAF inhibitors
BRAF/MEK inhibition
IJMS | Free Full-Text | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
